The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
If someone on our board has any sense they would pitch at the upcoming conference towards big pharma companies and governments along the lines of our broad spectrum antiviral that can be stockpiled as a treatment to prevent death in the event of future pandemics and virus’ that the world is not prepared for.
If we can get that message out there, then we could get a platform trial or a JV with big pharma.
The question is, can Marsden or anyone at SNG get that message across properly and get the JV, platform trial or EUA we need?
Tommy, I haven’t seen you criticise Marsden once.
Hmmm, strange. Even the most supportive investors of Synairgen in the past are now expressing their frustration at Marsden’s incompetence. But you just seem to take aim at myself or others who don’t listen to your usual daily ramps.
You haven’t said what you think of Marsden?
Tatty, I think that’s quite a good comparison actually, Gavin Williamson and Richard Marsden.
The stupid thing is about this forum is that no one can actually defend Marsden, everyone knows he’s hopeless. What they’ll do is take aim at people they dislike and nitpick. In the meantime we are stuck with a completely useless CEO and CSO that will never be able to bring SNG001 to market.
Lima, I’m not in charge of hiring or firing. I’m expressing my opinion.
What’s your opinion on Marsden’s performance as CEO for the last 17 years?
As a shareholder, how do you think he has performed, would you call him a success for the company?
The irony is when daneeka comes along and says exactly what I’ve been saying for the past 6 months.
Drug has potential, lots of potential. But the company itself is hopeless. It’s still acting like a university research team. Although maybe I’m being rude to university research teams because they would have put on a much more considered and concise trial than SPRINTER.
JC, I agree with that.
Mass email the company telling them of our disapproval if they fail to apply for EUA after A2P2 and deep dive.
In the email we need to tell these idiots that both Adagio and NRX have applied for EUA, despite their failed trials. Adagio doesn’t have A2P2 either.
We have more data than each of those companies.
Their job is to bring this drug to market and then sell it, they should only be able to keep their jobs if they can do them properly, otherwise they have to go. Marsden hasn’t been able to do it in 17 years, it’s pathetic now.
J cit, agree.
I think he should be given 3 months.
In those 3 months he has a choice. He can either get the ACTIV2P2 data and SPRINTER deep dive data and apply immediately for EUA if it is any good.
If he does that, he can retain his role, for an extra 6 months.
If he doesn’t get the flipping data within the next 3 months and apply for EUA then he’s got to go.
17 years of this crap and he stays on.
What’s next? Another 17 years of this rubbish?
If he stays on, plodding along slowly collecting his cash and bonus’ until retirement then Synairgen are not going to be commercialised in the next 17 years to come.
Trinity, nice post, here are a couple of reasons why I want Marsden gone.
1. 17 years of failure.
It is a biotech company’s job to bring a drug to market, Marsden has been CEO for 17 years and in that time he has failed to bring SNG001 to market.
2. Marsden shows little optimism and little understanding of how angry shareholders are. Rather than coming out, explaining what the next steps are, talking about possible EUA application if the deep dive data is any good, he says sweet FA.
The job of a CEO is to plan for the future and map out the near term future of a company for shareholders. We have seen and heard nothing from Marsden, compounded by the fact that Synairgen have suffered their largest embarrassment in the last two decades.
3. The speed at which it took to get fund raise done and complete the trial. Marsden should be in charge of timelines, he is also in charge of his staff, the buck stops with him. The lack of haste (given we are in a global pandemic where drugs are needed rapidly) was astonishing. Never in interview did he ever show bullish optimism or talk about the need for his drug to be approved to save lives.
There are three huge factors in why he needs to go.
We need a new, younger and far more ambitious CEO who REALLY WANTS to take SNG001 to market.
It would be perfect to recruit a young global senior VP at a big pharma who wants to carve their own way, take on Synairgen and bring the drug to market.
If that means that the CEO needs to sack Monk and others then so be it. Monk has been utterly useless as well. One example is the speed of which it took to get IV results for Omicron, it took about four months to write an RNS for a five day long lab experiment.
What exactly are these people doing every day?
It’s the CEO’s job to explain to shareholders and outline the future plans of the company.
It’s the CSO job to plan and have the clinical studies and trials in place.
Both Marsden and Monk have proven themselves to be utterly hopeless.
Why do you continue to defend Marsden?
17 years of failure.
He had £90 million at his disposal and took 2 years to end up with the biggest laughing stock trial throughout the entire pandemic.
17 years and Synairgen is still a research company with no drug to market.
Why do you continue to defend this guy and why do you go out of your way to discredit anyone who speaks against him?
Do you work for Marsden or something? The guy is f11cking beyond useless.
Burstead, dunk, tommy, manifesto (although I’m borderline about manifesto) are just ramping the stock and day trading.
They only want to attack anyone that says anything negative about the stock because they want to buy/sell multiple times daily.
It’s all about ramping the stock on here and then selling for a quick buck, Belfort style rats that ramp and sell. That’s the only possible explanation I can see for any rampers on this stock now.
Ramp and sell.
Illegal in financial institutions but on this board of anonymity they can get away with it.
dunk, you really are stupid, aren’t you?
Why do you think I’m here? I’m here because I invested over 60k at the fund raise. I trade half my shares and have a holding in SNG. I want to make money from my investment (as do almost all other investors) hence why I want to talk to other investors who also own shares in the company about the possibility of REMOVING THE SH11TE CEO THAT WE HAVE, so that we can progress to commercialisation and then make lots of money.
I don’t like having a failed CEO still leading this company after he’s had 17 years and multiple attempts to bring it to market. It’s time he goes and allows a young a ambitious CEO in.
Why on earth are you here?
I’m guessing to ramp and then day trade, like the RAT that you are.
Costs, agreed, Marsden is utterly hopeless.
How he retains any credibility amongst people on here is beyond me.
Failed in 17 years, continues to earn six figure salary and continues to deliver no revenue for Synairgen at all.
How useless does someone have to be before they are sacked? Hopefully Polygon can force him out and we can get a new young ambitious CEO. Someone early 40’s who has excelled at big pharma and got to senior global VP level who wants to make their own way in pharma and bring SNG001 to commercialisation.
If we could get someone like that on board then we could bring Synairgen to market within a couple of years. With Marsden at the helm, forget it, in a decade we will be in the same stage, still a university research company.
martin, indeed. But nevertheless that’s a good gamble for Poly to take, given that it doesn’t look like the team and CEO at Synairgen are able to do much.
There is every possibility we stay at these rubbish levels with our dreadful CEO.
Size82 they did pay over 200p.
But the AIM rule is that the highest price paid over the last 12 months must be offered.
If Polygon sit back and wait another 11 more months, then their highest price they’ve paid within 12 months will be around 20p. So they can make a 20p offer per share for Synairgen.
Poly can just wait. There’s no rule that they must buy over 30% and make an offer now. They can go over 30% in a years time and then offer to buy the company out then at a super cheap price.
Wigster, unfortunately it won’t even be 2025 at this rate.
If it was 2025 then we just sit back for 3 years and wait.
At this competency and with this team in place Synairgen will never get their product approved. The CEO has been trying for 17 years to get it approved and failed, why would he be able to get it approved after another failed trial?
A joint venture is needed, or a platform trial where somebody else has designed and is carrying out the trial. Synairgen have proven themselves to be totally useless when it comes to trial design or getting any results (as demonstrated by lack of any blood bank results from SPRINTER). If the inhaled interferon is going to go to market it will need a much more experienced team to design and conduct a proper trial suited for it. Synairgen and in particular their CEO Marsden have proven failures for a very long time at doing this.
If we get a platform trial then maybe approval within 12-18 months.
If we get JV then maybe trial and approval within 12-18 months.
If Synairgen have to do a fund raise and go it alone again = not going to work. They aren’t competent enough to get this drug to market.
dunk, are you working for Polygon?
You disgust me. Conning people out of their money on here. Rat.
You know full well that the highest price of a 12 month period must be offered. So all Polygon have to do is wait 12 months and then they can offer 20p per share.
tommy why even mention Polygon maybe paying 207p per share?
YOU KNOW THIS ISN’T GOING TO HAPPEN.
Stop ramping up the company and prospects when you know full well that nothing is happening until at least May, when they are doing a presentation.
Your plan is simple, ramp the stock up whilst knowing full well the price will fluctuate and you can trade until mid May, whilst you continue to ramp on here with stupid comments that you made about Polygon spending 207p a share (why they f11ck would they do that? It’s ridiculous to even jest about it).
Aether, no it won’t be, as we don’t have approval.
Again, it’s important not to give any false rays of hope until we actually get some decent news with this company. So far, since ACTIV2 P2 news, it has only been negative news.
After everyone got burnt from this stock badly, I don’t want to see Jordan Belfort rampers suckering people in and trading this stock at the expense of others who will lose their money.